Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 14/20 | 0.40 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.40 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5485963 | 0.83 | MEN1 (0.50) | MEN1KMT2AMAPK1HSD17B10L3MBTL1 | |
| SCHEMBL5495832 | 0.82 | MEN1 (0.49) | MEN1KMT2AMAPK1HSD17B10L3MBTL1 | |
| SCHEMBL22911938 | 0.82 | MEN1 (0.57) | MEN1KMT2AMAPK1HSD17B10L3MBTL1 | |
| SCHEMBL5025329 | 0.81 | NCF1 (0.53) | MEN1KMT2AMAPK1 | |
| SCHEMBL5486382 | 0.79 | MEN1 (0.52) | MEN1KMT2AMAPK1L3MBTL1NPY5R | |
| SCHEMBL5491050 | 0.78 | MEN1 (0.50) | MEN1KMT2AL3MBTL1NPY5R | |
| SCHEMBL5486783 | 0.77 | KMT2A (0.51) | MEN1KMT2AMAPK1HSD17B10L3MBTL1 | |
| SCHEMBL5485920 | 0.74 | KMT2A (0.48) | MEN1KMT2AMAPK1HSD17B10L3MBTL1 | |
| SCHEMBL5491482 | 0.73 | MEN1 (0.60) | MEN1KMT2AMAPK1HSD17B10L3MBTL1 | |
| SCHEMBL5490225 | 0.73 | MEN1 (0.60) | MEN1KMT2AMAPK1HSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205309-B2 | Quinazoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1560816-A1 | QUINAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-10 | — | — | EP | disclosed |
| US-20040029901-A1 | Quinazoline derivatives | HOFFMANN-LA ROCHE INC. | 2004-02-12 | — | — | US | disclosed |
| WO-2004005265-A1 | QUINAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029901-A1 | Quinazoline derivatives | GPR119, NQO2, CYP7A1 | MEN1 1326/4885KMT2A 1664/4885MAPK1 1442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.